Article
Behavioral Sciences
Yingchun Xiang, Yumiao Niu, Yacong Xie, Shishuo Chen, Feng Zhu, Weida Shen, Ling-Hui Zeng
Summary: The study investigated the phosphorylation levels of the RhoA/Rho kinase pathway in response to KA treatment, and found that KA induces activation of the pathway leading to inhibition of neurite outgrowth. Pretreatment with fasudil reversed this effect, suggesting that inhibiting the RhoA/Rho kinase pathway may be a potential treatment for seizure-induced neurite injury.
BRAIN AND BEHAVIOR
(2021)
Article
Endocrinology & Metabolism
Yi-Hsuan Wei, Shu-Lang Liao, Sen-Hsu Wang, Chia-Chun Wang, Chang-Hao Yang
Summary: Simvastatin and ROCK inhibitor Y-27632 have been shown to inhibit the fibrosis process induced by TGF-beta, potentially through suppressing the RhoA/ROCK/ERK and p38 MAPK signaling pathways.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Claudia M. Lucero, Lucas Marambio-Ruiz, Javiera Balmazabal, Juan Prieto-Villalobos, Marcelo Leon, Paola Fernandez, Juan A. Orellana, Victoria Velarde, Juan C. Saez, Gonzalo Gomez
Summary: This study found that the activation of Cx43 hemichannels and inhibition of cell-cell coupling during inflammation may contribute to oxidative stress and damage of mesangial cells through the RhoA/ROCK pathway.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell Biology
Travis A. Witkowski, Bin Li, Jason G. Andersen, Bhavna Kumar, Edmund A. Mroz, James W. Rocco
Summary: Conditional reprogramming is an effective cell culture technique for rejuvenating epithelial cells. Y27632, a compound that inhibits ROCK isoforms, promotes the process by increasing cell adherence, cell cycle progression, and expression of stem cell markers. Knockout experiments showed that ROCK inhibition alone is insufficient for cell propagation, indicating that Y27632 acts through additional mechanisms. The study suggests that ROCKs play a role in epidermal stem cell renewal, but other pathways are also involved.
JOURNAL OF CELL SCIENCE
(2023)
Article
Veterinary Sciences
Michaela Melzer, Janina Burk, Deborah J. J. Guest, Jayesh Dudhia
Summary: The Rho/ROCK inhibitor Y-27632 had no effect on proliferation activity and cell senescence in equine ASC and BMSC, as shown by the study.
FRONTIERS IN VETERINARY SCIENCE
(2023)
Article
Chemistry, Multidisciplinary
Taslim A. Al-Hilal, Mohammad Anwar Hossain, Ahmed Alobaida, Farzana Alam, Ali Keshavarz, Eva Nozik-Grayck, Kurt R. Stenmark, Nadezhda A. German, Fakhrul Ahsan
Summary: The study developed a hypoxia-activated prodrug of fasudil that selectively suppresses ROCK activity under hypoxic conditions, exhibiting antiproliferative effects on disease-afflicted pulmonary arterial smooth muscle cells and pulmonary arterial endothelial cells. The prodrug has a long plasma half-life and does not affect systemic blood pressure.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Biochemistry & Molecular Biology
Yosuke Nagai, Keiichiro Matoba, Hideji Yako, Shinji Ohashi, Kensuke Sekiguchi, Etsuko Mitsuyoshi, Kazunori Sango, Daiji Kawanami, Kazunori Utsunomiya, Rimei Nishimura
Summary: The activation of small GTPase Rho and its effector Rho-kinase (ROCK) in the diabetic kidney has been shown to play an important role in the progression of diabetic kidney disease. This study demonstrates that inhibiting the isoform ROCK1 can restore fatty acid oxidation in the glomeruli. The inhibition of ROCK1 optimizes fatty acid utilization and redox balance in mesangial cells through AMPK phosphorylation and induction of PGC-1a, suggesting ROCK1 as a promising therapeutic target for diabetic kidney disease.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Review
Behavioral Sciences
RuoLan Cai, YangYang Wang, ZhenTing Huang, Qian Zou, YinShuang Pu, Changyin Yu, Zhiyou Cai
Summary: ROCK activation can promote the occurrence of Alzheimer's disease and may involve a positive feedback loop between Aβ and ROCK. Additionally, ROCK can also promote the formation of neurofibrillary tangles and exacerbate neuroinflammatory responses.
BEHAVIOURAL BRAIN RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Chengyu Xiang, Yi Yan, Dingguo Zhang
Summary: The study demonstrates that fasudil has a protective effect on doxorubicin-induced nephrotoxicity by inhibiting oxidative stress, DNA damage, apoptosis, and cell senescence through targeting the RhoA/Rho kinase (ROCK) signaling pathway.
JOURNAL OF PHARMACOLOGICAL SCIENCES
(2021)
Review
Immunology
Anuja Singh, Tapan Behl, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Vasudevan Mani, Amal M. Alsubayiel, Saurabh Bhatia, Ahmed Al-Harrasi, Simona Bungau
Summary: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by dysregulated inflammatory reactions and T lymphocyte invasion into the joints. Research suggests that the Rho enzyme family and the ROCK regulatory cascade play a role in the pathogenesis of autoimmune diseases, with ROCK activation observed in RA patients and blocking ROCK showing potential for reducing inflammatory cytokines.
INFLAMMOPHARMACOLOGY
(2021)
Article
Cell Biology
Zeina Harhous, Wissam H. Faour, Nabil El Zein
Summary: The study revealed that VIP induced activation of phospho-AKT and phospho-ERK1/2 levels in macrophages in a GTP-RhoA-GTPase-dependent manner. VIP also increased intracellular release of H2O2 and calcium through PLC and GTP-RhoA-GTPase, and induced the expression of CD11b, CD35, CD66, and MMP9. Furthermore, VIP activated P38 MAPK through the cAMP/PKA pathway but independently of PLC and RhoA signaling, with these effects mediated via the FPRL1 receptor.
INFLAMMATION RESEARCH
(2021)
Article
Cell Biology
Xiaoqi Han, Siyuan Jiang, Yinmin Gu, Lihua Ding, Enhao Zhao, Dongxing Cao, Xiaodong Wang, Ya Wen, Yongbo Pan, Xin Yan, Liqiang Duan, Minxuan Sun, Tao Zhou, Yajuan Liu, Hongbo Hu, Qinong Ye, Shan Gao
Summary: In this study, it was found that HUNK inhibits EMT and metastasis of CRC cells through its kinase-dependent interaction with GEF-H1. HUNK directly phosphorylates GEF-H1 at serine 645, leading to activation of RhoA and subsequent phosphorylation of LIMK-1/CFL-1, resulting in stabilization of F-actin and inhibition of EMT. Clinically, decreased levels of HUNK expression and phosphorylation of GEF-H1 at serine 645 were observed in CRC tissues with metastasis, indicating their potential as biomarkers for metastasis.
CELL DEATH & DISEASE
(2023)
Article
Oncology
Oscar Maiques, Bruce Fanshawe, Eva Crosas-Molist, Irene Rodriguez-Hernandez, Alessia Volpe, Gaia Cantelli, Lena Boehme, Jose L. Orgaz, Faraz K. Mardakheh, Victoria Sanz-Moreno, Gilbert O. Fruhwirth
Summary: This study utilized bioinformatic analyses, in vitro validation, and tissue histology to investigate the mechanisms and effects of metastasis-inhibiting drugs in melanoma. The Rho kinase-myosin II pathway was identified as a potential therapeutic target, leading to the proposal of a migrastatic drug development pipeline.
BRITISH JOURNAL OF CANCER
(2021)
Article
Pharmacology & Pharmacy
Keiichiro Matoba, Kensuke Sekiguchi, Yosuke Nagai, Yusuke Takeda, Hiroshi Takahashi, Tamotsu Yokota, Kazunori Utsunomiya, Rimei Nishimura
Summary: ROCK plays a critical role in diabetic nephropathy, with its substrate MYPT1 showing increased phosphorylation in affected patients. Analysis of patients with diabetes treated with fasudil revealed a reduction in proteinuria and potential renal protective effects.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Behnaz Lahooti, Racheal G. Akwii, Dhavalkumar Patel, Siavash ShahbaziNia, Margarita Lamprou, Mahboubeh Madadi, Thomas J. Abbruscato, Aristotelis Astrinidis, Ulrich Bickel, Abraham Al-Ahmad, Nadezhda A. German, George Mattheolabakis, Constantinos M. Mikelis
Summary: This study successfully targeted endothelial cells by generating CD31-targeting liposomes with encapsulated Fasudil, which inhibited RhoA signaling and angiogenic functions. It provides a promising strategy for anti-angiogenic therapy.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2023)
Article
Biochemistry & Molecular Biology
Mehtap Pektas, Akif Hakan Kurt, Ismail Un, Rukiye Nalan Tiftik, Kansu Buyukafsar
Meeting Abstract
Urology & Nephrology
B. Turna, M. Cinar, E. Canda, E. Orhan, N. Nalan, B. Semerci, O. Nazli, K. Buyukafsar
EUROPEAN UROLOGY SUPPLEMENTS
(2008)
Article
Cardiac & Cardiovascular Systems
R. Nalan Tiftik, Ayse Erol, Mehtap G. Cinar, Havva Kubat, Mustafa Ark, Sibel Ulker, Kansu Buyukafsar
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
(2008)
Article
Urology & Nephrology
Selahittin Cayan, Baris Saylam, Nalan Tiftik, Nil Dogruer Unal, Duygu Dusmez Apa, Ozan Efesoy, Burak Cimen, Murat Bozlu, Erdem Akbay, Kansu Buyukafsar
Meeting Abstract
Oncology
A. Ata, A. Ozcimen, H. Kurt, N. Tiftik, A. Arican, K. Buyukafsar
ANNALS OF ONCOLOGY
(2012)
Meeting Abstract
Oncology
Alper Ata, Ata Ozcimen, Hakan Kurt, Nalan Tiftik, Ali Arican, Kansu Buyukafsar
JOURNAL OF CLINICAL ONCOLOGY
(2012)
Article
Urology & Nephrology
Burak Turna, Mehtap G. Cinar, Abdullah E. Canda, Elif C. Orhan, Nalan R. Tiftik, Oktay Nazli, Kansu Buyukafsar
Meeting Abstract
Urology & Nephrology
Burak Turna, Mehtap G. Cinar, Erdem A. Canda, Bulent Semerci, Elif C. Orhan, Nalan R. Tiftik, Oktay Nazli, Kansu Buyukafsar
JOURNAL OF ENDOUROLOGY
(2007)
Article
Pharmacology & Pharmacy
Muradiye Nacak, Zulal Erbagci, Kansu Buyukafsar, Ahmet Sencer Yurtsever, Rukiye Nalan Tiftik
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
(2007)
Article
Pharmacology & Pharmacy
Kansu Buyukafsar, Ipek Yalcin, A. Hakan Kurt, R. Nalan Tiftik, Sahan-Firat Seyhan, Fazilet Aksu
EUROPEAN JOURNAL OF PHARMACOLOGY
(2006)
Article
Pharmacology & Pharmacy
Kansu Buyukafsar, Tamer Akca, Rukiye Nalan Tiffik, Seyhan Sahan-Firat, Suha Aydin
EUROPEAN JOURNAL OF PHARMACOLOGY
(2006)
Article
Pharmacology & Pharmacy
S Sahan-Firat, RN Tiftik, M Nacak, K Büyükafsar
EUROPEAN JOURNAL OF PHARMACOLOGY
(2005)
Article
Pharmacology & Pharmacy
O Köksel, Ç Yildirim, RN Tiftik, H Kubat, L Tamer, L Cinel, MB Kaplan, U Degirmenci, A Özdulger, K Büyükafsar
EUROPEAN JOURNAL OF PHARMACOLOGY
(2005)